Koya Medical, founded in 2018, is a transformative healthcare venture with a mission to treat cancer-related chronic lymphedema and venous diseases through an innovative patient-centric platform. Our multidisciplinary team is headquartered in the San Francisco Bay Area.
Andy has deep and wide experience in innovation, technology, and commercialization in the healthcare field. He holds a Ph.D. in biomedical engineering from the School of Medicine at University of North Carolina-Chapel Hill, M.S. in materials science and engineering from University of Arizona, and Bachelor's degree in chemical engineering from University of Madras.
Stanley Rockson, MD, FACP, FACC is the Allan and Tina Neill Professor of Lymphatic Research and Medicine at Stanford University School of Medicine. He serves concurrently as the Stanford’s Chief of Consultative Cardiology and the Director of the Stanford Center for Lymphatic and Venous Disorders. Dr. Rockson is Editor-in-Chief of Lymphatic Research and Biology and sits on the editorial board of Angiology.
Dr. Armer, Ph.D., RN, FAAN is a professor at the MU Sinclair School of Nursing and Director of Nursing Research at Ellis Fischel Cancer Center. In 2000 she was appointed to the Medical Advisory Committee of the National Lymphedema Network (NLN). In 2008, she became the founding director of the American Lymphedema Framework Project.
Dr. Feldman, MD, CLT-LANA is a senior attending physician at NorthShore University HealthSystem in Evanston, Illinois and is the Director of the Lymphedema Treatment Program. Dr. Feldman is a Senior Clinician Educator, University of Chicago Pritzker School of Medicine. He is currently the Co-Director of the American Lymphedema Framework Project, established in 2008, and has been a member of the National Lymphedema Network Medical Advisory Committee since 1998.
Roman Skoracki, MD, is a member of the Cancer Control Program at the OSUCCC – James, where his research focuses on clinical outcomes of breast cancer. Dr. Skoracki is also the division chief of oncologic surgery at The Ohio State University Comprehensive Cancer Center and also one of the few surgeons who performs the procedure in the United States, about the unique nature of preventive lymphedema-relieving surgery, how it is performed and the potential benefits for patients.
Jane Wigg, RGN, MSc has been at the forefront of lymphoedema management for over 20 years, commencing one of the first lymphoedema clinics in the UK. In 2002, Jane also commenced the Lymphoedema Training Academy (LTA), as a means of providing quality education in Manual Lymphatic Drainage and other treatments for therapists. She has is also director of LymphVision which provides world-leading NIRF Lymphatic Imaging and has already opened 4 clinics in the UK over the past year.
Dr. Vaughan Keeley is a Consultant Physician specializing in Lymphoedema in the UK. He developed the Lymphoedema service in Derby, Nottingham and Mansfield. The service has recently been endorsed by NHS England as a specialist service for pediatric and primary Lymphoedema and is part of VascERN, the European Reference Network for Vascular Rare Diseases. He developed and validated the LYMQOL quality of life tool.
Josh has spent over 25 years in the healthcare industry working across a broad range of responsibilities and companies ranging from early stage product development and innovation to public offerings, mergers and acquisitions for mature companies. He currently serves as a VenturePartner at SightLine partners. Prior to SightLine, he was a Managing Director at Split Rock Partners. He has been a lead investor and board member in companies with an aggregate, realized value of over $2 billion.
Kal is a Silicon Valley-based serial entrepreneur and institutional investor. He is a partner at Zuehlke Ventures the co-founder of the Catalyst Technology Innovation Group (CTIG), a medical project generator focused on selecting and financing companies addressing unmet clinical needs.
Andrew Offer, CFA, joined SHD in 2007 and is the CEO. He serves on the board of directors for most SHD portfolio companies, in addition to acting as the CFO for multiple portfolio companies. Prior to SHD, he was an associate at the Dallas-based Value Management Group (VMG Health), where he focused on valuation exclusively in the healthcare industry.